wellrank.ai

My insurance denied Wegovy. Are compounded GLP-1s my best option?

ClaudediscoveryCollected Jul 9, 2026, 09:38 UTC

Verbatim response from Claude

This is a really common situation right now. Here's an honest breakdown:

Compounded GLP-1s - What to Know

Legitimate options exist, but proceed carefully:

  • Hims & Hers, Ro, and Henry Meds offer compounded semaglutide through licensed telehealth providers
  • These can be significantly cheaper ($200-400/month vs. $1,300+ for brand name)

Real concerns:

  • FDA has flagged quality/safety issues with some compounding pharmacies
  • Compounded versions aren't FDA-approved
  • Now that Wegovy is off the shortage list, many compounders must stop by May 2025 per FDA rules - so availability is changing

Other Options Worth Trying First

  • Appeal your insurance denial - ask your doctor for a peer-to-peer review, which reverses denials surprisingly often
  • Novo Nordisk's savings program - can bring Wegovy to ~$0-185/month if you have any commercial insurance
  • Ozempic (same drug, often better covered for diabetes diagnosis)
  • Zepbound/Mounjaro (tirzepatide) - sometimes easier to get covered

My Honest Recommendation

Before committing to compounded versions, try appealing and check manufacturer savings cards. If you go compounded, stick to established telehealth platforms with verified pharmacy partners rather than random online sources.

Want help with any specific step?

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.